Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

ASEP Medical Holdings Inc (ASEP) AI Stock Analysis

TSE:ASEP

ASEP Medical Holdings Inc

(CNQX:ASEP)

Select Model
Rating:42Neutral
Price Target:CAD 0.10â–¼(-4.00% Downside)
Action:reiterated
Date:10/11/26

The score is held down primarily by weak financial performance (heavy losses and ongoing cash burn despite low leverage). Technicals add further pressure with a bearish trend (price below key moving averages and negative MACD). Valuation contributes negatively due to a loss-making profile (negative P/E) and no dividend support.

Positive Factors
Low LeverageVery low leverage reduces fixed financial obligations and limits balance-sheet risk while ASEP develops its biotech programs. This gives management more flexibility to allocate capital toward research and commercialization without the immediate burden of substantial debt service.
Negative Factors
Persistent Cash BurnOngoing negative operating and free cash flow means ASEP is not yet funding its activities internally. Continued burn can require additional financing, which may constrain strategic choices and increase the risk of dilution before revenue reaches a sustainable scale.

ASEP Medical Holdings Inc (ASEP) vs. iShares MSCI Canada ETF (EWC)

-100%-75%-50%-25%0%25%50%TSE:ASEP-80.00%EWC+23.59%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
CAD 1.09M
Dividend Yield
―
Average Volume (3M)
18.45K
Price to Earnings (P/E)
-0.3
Beta (1Y)
-0.81
Revenue Growth
13.48%
EPS Growth
64.30%
Country
Canada
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ASEP Medical Holdings Inc Business Overview & Revenue Model

Company Description

Asep Medical Holdings Inc. is dedicated to advancing medical solutions, primarily through its subsidiary, ASEP Medical Inc. The company's core focus involves pioneering an early diagnostic method for Sepsis, as well as developing innovative peptide-b...

ASEP Medical Holdings Inc Financial Statement Overview

Summary

Financials reflect an early-stage biotech profile: revenue remains modest/flat while losses are extreme (negative gross profit and very large net losses). Cash flow is still negative with ongoing burn, though free cash flow improved versus the prior annual period. The balance sheet is a relative strength due to low leverage, but equity has declined and returns are deeply negative.

Income Statement

18Very Negative

Balance Sheet

56Neutral

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMJun 2026Sep 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue336.77K336.77K297.59K21.14K00
Gross Profit-196.75K-374.59K297.59K-113.74K-155.40K-177.18K
EBITDA-1.93M-1.85M-2.36M-8.14M-4.56M-2.06M
Net Income-4.92M-4.92M-8.27M-8.23M-5.76M-2.30M
Balance Sheet
Total Assets8.72M8.72M14.32M25.61M27.08M30.72M
Cash, Cash Equivalents and Short-Term Investments153.65K153.65K45.68K64.72K2.13M5.29M
Total Debt230.00K230.00K314.82K20.00K00
Total Liabilities4.38M4.38M4.87M3.05M528.16K144.20K
Stockholders Equity2.33M2.33M4.94M12.61M15.47M18.26M
Cash Flow
Free Cash Flow-1.02M-1.02M-337.13K-2.72M-3.61M-1.31M
Operating Cash Flow-1.02M-1.02M-337.13K-2.71M-3.61M-1.19M
Investing Cash Flow749.37K749.37K-380-4,471124.80K146.08K
Financing Cash Flow402.94K402.94K291.98K651.40K330.00K6.34M

ASEP Medical Holdings Inc Technical Analysis

Technical Analysis SentimentNegative
Last Price0.10

Price Trends

50DMA0.16Negative
100DMA0.14Negative
200DMA0.20Negative

Market Momentum

MACD-0.01Positive
RSI39.16Neutral
STOCH33.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASEP, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.16, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.16 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ASEP.

ASEP Medical Holdings Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:ASEP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:DRUGTSE:DRUG47NeutralCAD 757.88M-26.55-12.56%――-117.77%
TSE:ASEPTSE:ASEP42NeutralCAD 1.59M-0.28-131.53%―13.48%64.30%

* Healthcare Sector Average

Performance Comparison

-50%0%50%TSE:ASEPTSE:DRUGTSE:MYNDTSE:IBOTSE:MBIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
TSE:ASEP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:ASEPASEP Medical Holdings Inc0.10-0.40-80.00%
TSE:DRUGBright Minds Biosciences Inc.77.004.195.75%
TSE:MYNDMynd Life Sciences Inc0.070.000.00%
TSE:IBOUniversal Ibogaine Inc0.010.000.00%
TSE:MBIOMindbio Therapeutics Corp.0.10-1.90-94.75%

ASEP Medical Holdings Inc Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Asep Medical Launches $900,000 LIFE Financing to Fund Biotech Acquisitions

Positive
Oct 9, 2026

Asep Medical Holdings Inc. plans to raise up to $900,000 through a non-brokered private placement under the Listed Issuer Financing Exemption, offering 9,000,000 units at $0.10 each, with attached warrants exercisable at $0.12 for 24 months. The fina...

Business Operations and StrategyPrivate Placements and Financing

Asep Medical Launches $900,000 LIFE Financing to Fuel Biotech Portfolio Growth

Positive
Oct 9, 2026

Asep Medical Holdings Inc. plans to raise up to $900,000 through a non-brokered private placement under the Listed Issuer Financing Exemption, offering 9,000,000 units at $0.10 per unit, each comprising one common share and a warrant exercisable at $...

Business Operations and StrategyPrivate Placements and Financing

Asep Medical Secures US$1 Million Loan to Fund Operations

Positive
Oct 9, 2026

Asep Medical Holdings Inc. has secured a non-revolving term loan facility of US$1 million from an arm’s length private lender to support short-term working capital, operating expenses and general corporate purposes. The loan, bearing 12% annual...

Business Operations and StrategyPrivate Placements and Financing

Asep Medical Retires Insider Debt via Share Issuance

Positive
Oct 2, 2026

Asep Medical Holdings Inc. has closed an agreement to settle CAD$288,250 in outstanding fees owed to creditors, directors, officers and advisors by issuing 2,882,500 common shares at a deemed price of CAD$0.10 per share. The share issuance remains su...

Business Operations and StrategyPrivate Placements and Financing

Asep Medical Settles $288,500 in Debt Through Share Issuance

Positive
Sep 18, 2026

Asep Medical Holdings Inc., a biotech-focused investment issuer based in Victoria, BC, leverages a portfolio of patented diagnostic and therapeutic technologies developed at the University of British Columbia. Its key holdings include Sepset Bioscien...

Business Operations and StrategyDelistings and Listing Changes

Asep Medical Restructures Stakes in ABT and Sepset While Preserving Economic Upside

Positive
Sep 5, 2026

Asep Medical Holdings Inc., a biotechnology-focused investment issuer based in Victoria, BC, concentrates on diagnostic and therapeutic medical technologies, including sepsis diagnostics through Sepset Biosciences and anti-biofilm solutions via ABT I...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 11, 2026